Clinical Crossroads in Ophthalmology™ 2022: Best Practices for Treating Complex Cases of Glaucoma and Diabetic Macular Edema (CME Symposium)
This educational activity will focus on the treatment considerations for patients with glaucoma and/or diabetic macular edema who also have comorbid conditions that may be challenging. Learners will be presented with evidence to develop long-term treatment strategies for patients with glaucoma and comorbid conditions as well as diabetic macular edema.
This educational activity is intended for ophthalmologists.
After completing this activity, participants will be better able to:
- Apply evidence to develop long-term treatment strategies for patients with glaucoma and comorbid conditions
- Develop long-term management plans for patients with diabetic macular edema who have comorbid conditions
|Thomas W. Samuelson, MD (Chair)|
Founding Partner and Attending Surgeon
Minnesota Eye Consultants
University of Minnesota
|Mark Hansen, MD|
Minnesota Eye Consultants
|Judy E. Kim, MD, FARVO, FASRS|
Professor, Ophthalmology and Visual Sciences
Professor, Graduate School of Biomedical Sciences
Director, Teleophthalmology and Research
Medical College of Wisconsin
|Jonathan S. Myers, MD|
Director, Glaucoma Service
Wills Eye Hospital
Professor of Ophthalmology
Sidney Kimmel Medical College
Thomas Jefferson University
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Mark Hansen, MD, has no relevant commercial relationships to disclose.
Judy E. Kim, MD, is an advisory board member of Adverum, Alimera Sciences, Allergan, Apellis Pharmaceuticals, Bausch & Lomb Incorporated, Clearside Biomedical, Inc, D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., Genentech, Inc, Novartis Pharmaceuticals Corporation, Outlook Therapeutics, Inc, and Regeneron Pharmaceuticals, Inc; and is a contracted researcher for Notal Vision.
Jonathan S. Myers, MD, is a consultant for AbbVie Inc, Aerie Pharmaceuticals, Inc, Ancora Biotech LLC, Avisi Technologies Inc, Elios Therapeutics, Glaukos Corporation, Haag-Streit Group, MicroOptx, and Olleyes Inc; and is a contracted researcher for AbbVie, Aerie Pharmaceuticals, Inc, Equinox, Glaukos Corporation, Guardian, Haag-Streit Group, Nicox, Olleyes Inc, Santen Inc, and Thea Pharmaceuticals Limited.
Thomas W. Samuelson, MD, is a consultant for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Belkin Vision, ELT Sight, Equinox, Glaukos Corporation, Imprimis Pharmaceuticals, Inc, Ivantis Inc, Johnson & Johnson Vision Care, Inc, MicroOptx, New World Medical, Inc, Ocuphire Pharma, Polyactiva Pty Ltd, Ripple Therapeutics, Santen Inc, Sight Sciences, TearClear, Valeant, ViaLase, and Zeiss; and has individual stocks and stock options in Belkin Vision, Equinox, Ivantis Inc, Ocuphire Pharma, Sight Sciences, TearClear, and ViaLase.
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS within the past 2 years, but that relationship has ended.
Other MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from AbbVie Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or AbbVie Inc.
©2022 MedEdicus LLC. 283.1
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation